世界中医药2018，Vol.13Issue(2)：366-369,4.DOI:10.3969/j.issn.1673-7202.2018.02.029
多柔比星脂质体联合复方红豆杉胶囊治疗晚期铂类耐药型卵巢癌的临床效果
Clinical Study of Liposomal Doxorubicin Combined with Hongdoushan Capsule in the Treatment of Advanced Platinum Resistant Ovarian Cancer
摘要
Abstract
Objective:To analyze the effectiveness of liposomal doxorubicin combined with Hongdoushan capsule in the treatment of advanced platinum resistant ovarian cancer.Methods:A total of 37 patients with advanced platinum resistant ovarian cancer were divided into combined group(20 cases)and single drug group(17 cases).The combination group was given the treatment of liposomal doxorubicin(30~40 mg/m2intravenously)and Hongdoushan capsule(0.6 g 3/d),and the single drug group was giv-en the treatment of liposomal doxorubicin alone.The short-term efficacy and toxicity were evaluated.ECG,left ventricular ejection fraction, myocardial enzyme changes were monitored to evaluate cardiac toxicity of liposomal doxorubicin.Results:Efficacy rate was 35%in combined group and 23.53%in single group.There was statistical significance between the two groups(P<0.05). The control rate for disease was higher in combined group than the single group,and there was statistical significance between the two groups(P<0.05).KPS score of the combined treatment group improved significantly better than the control group(65%vs 47.06%).The incidences of nausea, vomiting, diarrhea and skin rash, dysfunction of hepatic function in the combined group were higher than the single drug group,while there were no differences between the two groups(P>0.05).Conclusion:Liposo-mal doxorubicin combined with Hongdoushan capsules in the treatment of advanced platinum resistant ovarian cancer has better clinical benefits and improvement for the quality of life than the single group.The therapy method is worthy to be popularized.关键词
多柔比星脂质体/复方红豆杉胶囊/顺铂/卡铂/卵巢癌Key words
Liposomal doxorubicin/Hongdoushan capsule/Cisplatin/Carboplatin/Ovarian cancer分类
医药卫生引用本文复制引用
宋琪,夏义欣,路泽军,赵春艳,张卓梅,陈琳,刘红..多柔比星脂质体联合复方红豆杉胶囊治疗晚期铂类耐药型卵巢癌的临床效果[J].世界中医药,2018,13(2):366-369,4.基金项目
中国人民解放军海军总医院创新培育基金项目(CXPY201503) （CXPY201503）
